Skip to content

Neural Mechanisms of Obsessive-compulsive Disorder (OCD) Treatment Failure

Cognitive and Neural Networks in Psychiatry (CNNP): Neural Mechanisms of Obsessive-compulsive Disorder (OCD) Treatment Failure (ERP in Silico)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05520398
Acronym
ERP in Silico
Enrollment
90
Registered
2022-08-29
Start date
2021-11-10
Completion date
2025-12-31
Last updated
2024-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder

Brief summary

The aim of this study is to understand why patients with obsessive-compulsive disorder (OCD) fail in therapy. To understand the neural mechanisms involved in exposure therapy that support success and clinical improvement in order to improve therapy outcomes for OCD patients.

Detailed description

A course of therapy is recommended for individuals with obsessive-compulsive disorder (OCD). It is usually a type of cognitive behavioural therapy (CBT) with exposure and response prevention (ERP). In this study the investigators assess patients pre-therapy and post-therapy evaluating symptom severity (measured by the Y-BOCS) and decision-making (measured by online questionnaires and computer-based behavioural tasks). To examine how decisions are formed in patients undergoing OCD CBT, how behaviour changes after a non-pharmacological therapy module and how it is associated to the alleviation of OCD symptoms. The study, which will recruit 90 patients, is based at University College London - Wellcome Centre for Human Neuroimaging. This study is a part of the Cognitive and Neural Networks in Psychiatry (CNNP) study.

Interventions

None listed

Sponsors

University College, London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of obsessive-compulsive disorder (OCD) * Fluent in written and spoken English * Normal/corrected to normal vision * Expecting to start OCD therapy

Exclusion criteria

* Autism spectrum disorder, psychosis, schizophrenia, addiction, substance abuse, bipolar, hoarding, or Tourette disorder * Hearing conditions: tinnitus, ear inflammation, hearing sensitivity, hearing loss, requires hearing aids * Colour blindness * Severe learning disabilities

Design outcomes

Primary

MeasureTime frameDescription
Yale-Brown obsessive compulsive scale (Y-BOCS)3 - 9 monthsThe Y-BOCS is a 10-item scale used to assess symptom severity in OCD.
Decision making and learning tasks3 - 9 monthsComputer-based behavioural task developed by the investigators to understand decision making in OCD.

Secondary

MeasureTime frameDescription
Anxiety Sensitivity Index (ASI-3)3 - 9 monthsSelf-report measure for anxiety sensitivity symptomatology.
Patient EX/RP Adherence Scale (PEAS)3 - 9 monthsSelf-report assessment for patient's therapy adherence.
Short form of Obsessive Beliefs Questionnaire (OBQ)3 - 9 monthsSelf-report assessment for obsessive beliefs.
Brief Experiential Avoidance Questionnaire (BEAQ)3 - 9 monthsSelf-report assessment for experiential avoidance.
State-Trait Anxiety Inventory (STAI)3 - 9 monthsMeasure of trait and state anxiety
Worry Domains Questionnaire - Short Form (WDQ-SF)3 - 9 monthsSelf-report assessment for worry.
The World Health Organization Quality of Life Brief Version (WHOQOL-BREF)3 - 9 monthsSelf-report assessment for quality of life assessment.
Sheehan Disability Scale (SDS)3 - 9 monthsSelf-report assessment for functional impairment.
International Cognitive Ability Resource (ICAR16)3 - 9 monthsMeasure to assess cognitive ability.
Zung Self-Rating Depression Scale (SDS)3 - 9 monthsSelf-report measure of depressive symptomatology.

Countries

United Kingdom

Contacts

Primary ContactTricia Seow, PhD
t.seow@ucl.ac.uk+44-(0)203-1087538

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026